Health Canada Approves Mayzent to Treat Active SPMS
Health Canada has approved Novartis‘s Mayzent (siponimod) for the treatment of adults with active secondary progressive multiple sclerosis (SPMS)…
Articles by Iqra Mumal, MSc
NeurologyLive, CMSC Offer Panel Series on Changes in MRI Guidelines for MS
NeurologyLive, a multimedia platform for specialists in that field, partnered with the Consortium of Multiple Sclerosis Centers (CMSC)Â for…
Flowonix’s Prometra II Pump System Receives FDA Approval for Use with Intrathecal Baclofen
The U.S. Food and Drug Administration (FDA) has granted approval to Flowonix Medical’s Prometra II Programmable Pump…
#ACTRIMS2020 – Keynote Speaker Peter Calabresi to Discuss Link Between Genetics and MS Severity
Specific mutations in genes that provide instructions to make two proteins —  called C3 and C1q — are linked to…
Insomnia and MS Given Intimate Focus in Short Film ‘Awake’ by UK Group
Insomnia, and all that repeat sleepless nights mean, burden a vast majority — 85% — of people with multiple…
Urinary Diversion Surgery May Be Used as Last Resort for Treating Urological Dysfunction in MS Patients, Study Shows
A surgical technique known as non-continent urinary diversion is an effective last-resort solution for treating urological dysfunction in…
‘Seeing’ Protein Density in Blood May Help in Early MS Diagnosis by Subtype, Work Suggests
A way of detecting the density of proteins in the blood, called “magnetic levitation” or MagLev, may aid in more…
MS Research Australia Grant to Help Doctors Better Diagnose, Treat Depression
A psychologist at Swinburne University of Technology in Melbourne has been awarded an incubator grant by MS Research Australia to…
Endonovo Therapeutics Issued Broad US Patent Covering Electromagnetic Treatment for MS
The United States Patent and Trademark Office (USPTO) has issued a patent to Endonovo Therapeutics for Application No.
Clinical Trial of Rhythmic Sound in Walking Rehab for MS Planned, MedRhythms Says
MedRhythms is planning to soon open a pilot clinical trial to assess the safety and efficacy of its MR-004, its…
CMSC Announces 4 Winners of Pilot Research Awards for 2019
The Consortium of Multiple Sclerosis Centers (CMSC) named four scientists the winners of its Pilot Research Award for 2019, given to…
Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says
People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction…
Managing Money Difficult for MS Patients with Cognitive Problems and Depression, Study Says
Effective money management, critical to independent living, is particularly  difficult for people whose multiple sclerosis (MS) affects executive thinking skills…
Breastfeeding Protects Against Postpartum Relapses in Women with MS, Review Finds
Women who breastfeed have a lower rate of multiple sclerosis (MS) relapses in the postpartum period compared to those…
EMD Serono, Canada Sign Agreement for Public Health Plan Funding of Mavenclad for RRMS
People with relapsing-remitting multiple sclerosis (RRMS) across Canada are a major step closer to having access to EMD…
CanProCo, Canadian Study into MS Progression, Given $1M in Support by Alberta
The Government of Alberta is investing CA$1 million into a research project that will follow for years a group…
Doctor Visits via Telemedicine Show Patient and Caregiver Satisfaction, Neurology Review Says
People with multiple sclerosis (MS) and their caregivers appear to be just as satisfied with a video evaluation given by…
Artificial Intelligence and Machine Learning May Help in Understanding MS Cause, Groups Say
Combining data science, artificial intelligence (AI), and machine learning to better identify patterns that may underlie the cause or causes…
MS Specialist to Lead Trial of Temelimab in Progressing Disease Without Relapses
GeNeuro is collaborating with clinical researchers at the Karolinska Institutet and the Academic Specialist Center (ASC) in Stockholm to…
Immunoadsorption May Be Superior to Plasma Exchange in Treating Steroid-resistant Relapses in MS
A blood-cleansing process known as immunoadsorption appears to be superior to plasma exchange in treating relapses that don’t respond to…
NMSS Awards $495K to Study Biomarkers in Phase 2 Trial of NurOwn in Progressive MS
BrainStorm Cell Therapeutics received a $495,330 grant from the National Multiple Sclerosis (MS) Society to support biomarker studies in…
Mayzent Approved in Australia as First Treatment for Secondary Progressive MS
Novartis’s Mayzent (siponimod) has been approved by Australia’s Therapeutic Goods Administration (TGA) for the treatment of secondary…
Depression, Fatigue Influence Health-related Quality of Life More Than Physical Impairment of MS, Study Reveals
Depression and fatigue have a more powerful influence on the overall health-related quality of life, compared to physical impairment, among…
Early Damage on Brain Scans and Greater 5-Year Disability Help Predict 30-Year Outcomes in MS, Study Finds
A 30-year study of outcomes in multiple sclerosis (MS) patients reports that radiological findings in the first year of disease…
Employed MS Patients Have Lower Productivity, Reduced Health-related Quality of Life, Study Shows
Employed individuals with relapsing-remitting multiple sclerosis (RRMS) have lower work productivity, reduced health-related quality of life, and use more…
Teva-Fingolimod, Generic and Bioequivalent Version of Gilenya, Available in Canada
Teva Canada announced that Teva-Fingolimod 0.5 mg capsules, a bioequivalent generic version of Novartis’ Gilenya (fingolimod), are now…
Study: 40% of SPMS Patients in Italy and Germany Unaware of Diagnosis
A new study shows that 40% of patients in Italy and Germany who have  secondary progressive multiple sclerosis (SPMS) are not aware of their diagnosis, indicating a need for significant improvement in patient-physician communication.
Brain Bank at Harvard Gets Potential $12.8M from NIH to Support Brain Donations for MS and Other Research
The Harvard Brain Tissue Resource Center at McLean Hospital, also known as the Brain Bank, has signed a new, potentially…
Interleukin-22 May Be Biomarker to Monitor How Well RRMS Patients Respond to Therapy
The levels of the inflammatory molecule interleukin-22 (IL-22) may be used as a potential biomarker to evaluate disease severity and…
Tysabri Treatment Leads to Disease Activity-free Status in Patients with Pediatric-onset MS
Early treatment with Tysabri (natalizumab) of patients with aggressive pediatric-onset multiple sclerosis is highly effective at achieving disease activity-free…